S&P 500

6.021,63

0,57%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NYSE
Amneal Pharmaceuticals Holding Co (AMRX)
Amneal Pharmaceuticals Holding Co (AMRX) Notícias

AMRX

Amneal Pharmaceuticals (AMRX)

Amneal Pharmaceuticals Holding Co

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NYSE:AMRX

1 2 3 4 5 6 7 8 9 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
05/09/2024	17:05	Business Wire	Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
20/08/2024	12:26	Business Wire	Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
14/08/2024	16:12	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
14/08/2024	06:56	IH Market News	UBS Beats Earnings Forecasts, Intel Divests Arm Holdings, Flutter Surges 9% in Premarket Trading, and More	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
09/08/2024	07:05	Business Wire	Amneal Reports Second Quarter 2024 Financial Results	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
07/08/2024	17:45	Business Wire	Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
29/07/2024	17:05	Business Wire	Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
11/07/2024	17:05	Business Wire	Amneal to Report Second Quarter 2024 Results on August 9, 2024	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
09/07/2024	17:05	Business Wire	Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
01/07/2024	09:00	Business Wire	Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
01/07/2024	09:00	Business Wire	Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
28/06/2024	09:00	Business Wire	Amneal Releases 2023 Environmental, Social and Governance Report	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
05/06/2024	09:00	Business Wire	Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
22/05/2024	17:05	Business Wire	Amneal to Participate at Upcoming Investor Conference	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
22/05/2024	17:05	Business Wire	Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
14/05/2024	17:45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
07/05/2024	17:18	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
03/05/2024	07:00	Business Wire	Amneal Reports First Quarter 2024 Financial Results	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
24/04/2024	09:00	Business Wire	Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
16/04/2024	09:00	Business Wire	Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
10/04/2024	09:00	Business Wire	Amneal to Report First Quarter 2024 Results on May 3, 2024	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
28/03/2024	17:05	Business Wire	Amneal to Ring the Nasdaq Closing Bell on April 2, 2024	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
25/03/2024	17:05	Business Wire	Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
22/03/2024	09:01	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
22/03/2024	09:01	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
01/03/2024	08:00	Business Wire	Amneal Reports Fourth Quarter and Full Year 2023 Financial Results	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
27/02/2024	10:00	Business Wire	Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
08/02/2024	18:05	GlobeNewswire Inc.	Amneal Announces Complete Response Resubmission for IPX203 New Drug Application	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
31/01/2024	18:05	Business Wire	Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024	NYSE:AMRX	Amneal Pharmaceuticals Holding Co
10/01/2024	10:00	Business Wire	Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension	NYSE:AMRX	Amneal Pharmaceuticals Holding Co